Biotechnology ETFs have surged in 2026, driven by advances in AI drug discovery and a wave of mergers and acquisitions. AI models are accelerating early-stage research, reducing costs, while large pharma companies are acquiring smaller firms to offset a looming $280 billion patent cliff by 2028. Leading biotech ETFs like XBI and SBIO have posted strong returns, reflecting growing investor interest amid a stabilizing regulatory environment and expected interest rate cuts. This trend highlights a structural shift in biotech investing, with AI innovation and corporate consolidation reshaping the sector's outlook.

More News (XBI)

Financials, industrials, and biotech ETFs show breakout signs as Big Tech slows, signaling a sector leadership shift.

As Big Tech stocks show signs of fatigue, Wall Street technician Katie Stockton highlights financials, industrials, and biotech sectors as potential new leaders based on technical breakouts. She recommends ETFs XLF (financials), XLI (industrials), an...

Technical Signals

Bullish

4 days ago